Pfizer Seeks Combination Therapy Path After Lung Cancer Drug Clinical Failure
nashnova research
Pfizer's experimental lung cancer drug sigvotatug vedotin missed its primary endpoint, but a subgroup showed over two months of extra survival — the company is now betting on a Phase III combo trial with Merck's Keytruda.
How exactly did this drug "fail"?
Sigvotatug vedotin is an ADC — an antibody-drug conjugate that straps a potent chemotherapy toxin onto an antibody, which delivers it directly to tumor cells like a guided missile.
In a pivotal Phase III trial for advanced, inoperable lung cancer, it failed the primary endpoint: no significant improvement in overall survival versus chemotherapy.
This means → the drug cannot win standalone approval on these data. Pfizer needs a new path forward.
Why isn't Pfizer giving up?
At the European Society for Medical Oncology annual meeting, Pfizer presented a post-hoc subgroup analysis: patients who had received fewer prior treatments lived more than two months longer on the drug than on chemo.
Chief oncology officer Jeff Legos said: "For patients whose life expectancy is under a year, two and a half months is actually very meaningful."
In plain terms = the overall trial missed, but among patients whose disease hadn't progressed as far — and whose bodies were in better shape — the drug did buy meaningful extra time.
What is the logic behind the combination bet?
Pfizer is running a new Phase III trial combining sigvotatug vedotin with Merck's blockbuster immunotherapy Keytruda, targeting non-small cell lung cancer patients.
Legos laid out three layers of logic: ① these patients have had fewer prior treatments, so their immune systems function better; ② better immunity → higher likelihood of responding to a combo regimen; ③ the two drugs may produce an additive effect in earlier treatment lines, and early data already show strong response rates.
This means → Pfizer's wager is that the previous trial picked patients who were too far along. Earlier-stage patients plus Keytruda backup could yield a different outcome.
Why does this drug matter so much to Pfizer?
Sigvotatug vedotin was a crown-jewel asset from Pfizer's $43 billion acquisition of Seagen.
The entire Seagen deal was a bet on the ADC platform — precision-delivering potent cancer-killing compounds to tumors, widely seen as the next generation of oncology treatment.
The pivotal trial failure directly undercuts the return thesis for that blockbuster acquisition. Whether the combination pathway delivers hinges on the ongoing Phase III results — and that trial is now the last main road Pfizer has left for this drug.
市场有风险，内容仅供研究参考，不构成投资建议。